Trial Profile
Rifaximin-treatment of Collagenous colitis: A prospective, double-blind, placebo-controlled study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Dec 2021
Price :
$35
*
At a glance
- Drugs Rifaximin (Primary)
- Indications Microscopic colitis
- Focus Therapeutic Use
- Acronyms XiCoCo
- 16 Dec 2021 Status changed from not yet recruiting to completed.
- 12 Sep 2018 New trial record